TransMedics Group (NASDAQ:TMDX) Stock Price Up 4.5% After Insider Buying Activity

TransMedics Group, Inc. (NASDAQ:TMDX) shares traded up 4.5% during mid-day trading on Tuesday following insider buying activity. The company traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492 shares. The stock had previously closed at $85.86.

Specifically, Director David Weill bought 1,336 shares of the stock in a transaction dated Friday, September 11th. The shares were acquired at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the acquisition, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analyst Ratings Changes

TMDX has been the topic of a number of recent research reports. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research note on Friday. TD Cowen reaffirmed a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research note on Tuesday, September 8th. UBS Group lowered their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $124.00 target price on shares of TransMedics Group in a report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $124.18.

TransMedics Group Trading Up 5.0%

The company’s 50 day simple moving average is $82.29 and its two-hundred day simple moving average is $89.90. The stock has a market cap of $3.12 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 1.13 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period in the prior year, the company posted $0.92 earnings per share. TransMedics Group’s quarterly revenue was up 20.7% on a year-over-year basis. Research analysts expect that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently bought and sold shares of the business. HB Wealth Management LLC grew its stake in shares of TransMedics Group by 0.7% during the first quarter. HB Wealth Management LLC now owns 14,843 shares of the company’s stock worth $1,476,000 after purchasing an additional 107 shares during the period. Total Clarity Wealth Management Inc. lifted its stake in TransMedics Group by 5.1% in the first quarter. Total Clarity Wealth Management Inc. now owns 2,322 shares of the company’s stock valued at $231,000 after buying an additional 112 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in TransMedics Group by 2.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,797 shares of the company’s stock worth $949,000 after purchasing an additional 162 shares during the period. HighTower Advisors LLC increased its holdings in TransMedics Group by 1.0% during the 4th quarter. HighTower Advisors LLC now owns 16,407 shares of the company’s stock worth $1,996,000 after purchasing an additional 170 shares in the last quarter. Finally, Values First Advisors Inc. raised its stake in shares of TransMedics Group by 3.1% in the 1st quarter. Values First Advisors Inc. now owns 5,944 shares of the company’s stock valued at $591,000 after purchasing an additional 181 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.